---
title: 'Clinical Daily Summary: What Happened on November 19, 2026'
headline: Study characterizes potentially fatal enterocolitis after cilta-cel CAR
  T therapy
description: Biogen also reported two-year diranersen results from an ongoing Alzheimer’s
  study, including data from its open-label extension.
url: https://thebench.bio/news/clinical/2026-11-19
topic: clinical
date: '2026-11-19'
covers:
- '2026-11-19'
date_published: '2026-11-19T12:03:10Z'
date_modified: '2026-11-19T12:03:10Z'
tags:
- Industry
- Clinical
sources: 3
publisher: TheBench.Bio
---

# Clinical Daily Summary: What Happened on November 19, 2026

**Study characterizes potentially fatal enterocolitis after cilta-cel CAR T therapy**

Biogen also reported two-year diranersen results from an ongoing Alzheimer’s study, including data from its open-label extension.

## Today in brief

A multicenter study classified 41 patients treated with cilta-cel as having immune effector cell-associated enterocolitis. Seventeen had died while the condition was active at last follow-up. [1] A separate MD Anderson cohort identified nine cases and found CAR T cells to be the principal cause in those patients. The reason for the gut’s vulnerability remains unclear. [2]

Biogen reported two-year diranersen results in early Alzheimer’s disease. In an ongoing open-label extension, the 60 mg twice-yearly group showed the largest reported effects across several measures. [3]

## Enterocolitis after cilta-cel was active at death in 17 patients

Researchers reviewed 54 suspected gastrointestinal toxicity cases from eight institutions and classified 41 of 53 evaluable patients as having enterocolitis after cilta-cel treatment for multiple myeloma. [1] Immunohistochemistry, a test that detects specific proteins in tissue, confirmed 31 cases. Researchers considered 10 probable. [1]

Among 1,308 recipients treated through September 2025, the estimated cumulative incidence was 3.0%. The authors cautioned that the referral-based estimate may not represent the wider population. [1] Symptoms began a median of 75 days after infusion. Of 40 patients with diarrhea, 34 had severe symptoms. [1]

At last follow-up, 13 patients had recovered, 11 still had symptoms, and 17 had died while enterocolitis was active. [1] Thirty patients required nutrition delivered directly into the bloodstream. Delayed neurological toxicity occurred in 17 patients. [1]

A separate MD Anderson cohort identified nine cases among 158 cilta-cel recipients, with estimated incidence of 5.1% at six months and 5.7% overall. [2] The investigators identified CAR T cells as the principal cause in those cases. CAR T cell persistence in blood was 100 times greater than in patients without enterocolitis. [2]

The MD Anderson team found no evidence that vector integration caused mutations. The reason for the gut’s vulnerability remains unclear. [2] The consortium authors called for systematic assessment and early targeted treatment of the potentially fatal condition. [1]

## Biogen reports diranersen results from an ongoing Alzheimer’s extension

Biogen reported two-year data from CELIA, a Phase II study of intrathecal diranersen in 416 people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. [3] At week 96 of the ongoing open-label extension, participants assigned to 60 mg every six months showed the largest reported effects across cognition, daily function, and disease progression measures. [3]

In that group, worsening on the CDR-SB measure was 38% slower than in placebo-equivalent controls, a 1.09-point difference. [3] Biogen also reported effects of 54% on ADAS-Cog13, 30% on ADCS-ADL-MCI, 38% on ADCOMS, 46% on iADRS, and 38% on MMSE. [3]

The trial’s primary outcome assessed dose response in CDR-SB change at week 76. The week-96 results came from an open-label extension, not the original placebo-controlled period. [3] Biogen said clinical benefits appeared at every tested dose and that treatment was generally well tolerated over two years, with no new safety concerns. [3]

## The day in numbers

- **17 of 41**: Patients with cilta-cel-associated enterocolitis who died while the condition was active at last follow-up. [1]
- **3.0%**: Estimated cumulative enterocolitis incidence among 1,308 cilta-cel recipients through September 2025. The authors cautioned that the referral-based estimate may not represent the wider population. [1]
- **38%**: Slower CDR-SB worsening reported for the 60 mg every-six-months diranersen group versus placebo-equivalent controls at week 96 of the open-label extension. [3]

## Also published

- [STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment](<https://www.statnews.com/2026/11/19/erasca-kras-targeted-treatment-new-data-pancreatic-cancer/?utm_campaign=rss>), STAT Biotech
- [Keeping Patients in the Loop as AI Enters Clinical Research: Q&A with Stacy Hurt](<https://www.pharmexec.com/view/keeping-patients-loop-ai-enters-clinical-research-stacy-hurt>), Pharmaceutical Executive
- [Mixed results for experimental Alzheimer's therapies at CTAD](<https://pharmaphorum.com/news/mixed-results-experimental-alzheimers-therapies-ctad>), pharmaphorum
- [The new reality of early‑phase diabetes trials](<https://pharmaphorum.com/rd/new-reality-early-phase-diabetes-trials>), pharmaphorum

## Sources

1. [Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy](<https://www.nature.com/articles/s41591-026-04783-y>), Nature Medicine, 2026-11-19
2. [Expansion and cytotoxicity of mucosal CAR\<sup\>+\</sup\> T cells in enterocolitis associated with BCMA CAR-T cell therapy](<https://www.nature.com/articles/s41591-026-04731-w>), Nature Medicine, 2026-11-19
3. [Biogen reports two-year Phase II data for diranersen in Alzheimer’s](<https://www.clinicaltrialsarena.com/news/biogen-two-year-phase-ii-data-diranersen-ad/>), Clinical Trials Arena, 2026-11-19

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.nature.com/articles/s41591-026-04783-y>
[2]: <https://www.nature.com/articles/s41591-026-04731-w>
[3]: <https://www.clinicaltrialsarena.com/news/biogen-two-year-phase-ii-data-diranersen-ad/>
